Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline-based protocol. A report from the spanish group PETHEMA

Haematologica

Volumn 86, Issue 8, 2001, Pages 807-813

  Hernandez J M ^a   Martin G ^a   Gutierrez N C ^a   Cervera, J ^a   Ferro, M T ^a   Calasanz, M J ^a   Martinez Climent J A ^a   Luno E ^a   Tormo, M ^a   Rayon C ^a   Diaz Mediavilla J ^a   Gonzalez M ^a   Gonzalez San Miguel J D ^a   Perez Equiza K ^a   Rivas, C ^a   Esteve, J ^a   Del Carmen Alvarez M ^a   Odriozola, J ^a   Maria Ribera J ^a   Sanz, M A ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Acute promyelocytic leukemia; Additional chromosomal changes, t(15; 17); Cytogenetics; Prognosis

Indexed keywords

ANTHRACYCLINE; GENE PRODUCT; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PROTEIN PML RAR ALPHA; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHROMOSOME 1; CHROMOSOME 3; CHROMOSOME 8; CHROMOSOME 9; CHROMOSOME ABERRATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HYBRID GENE; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME; TRETINOIN;

EID: 0034855778     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. 15/17 Translocation, a consistent chromosomal change in acute promyelocytic leukaemia
2. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus
3. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
4. Cytogenetic studies in acute promyelocytic leukemia: A survey of secondary chromosomal abnormalities
5. Secondary chromosomal abnormalities in acute leukemias
6. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): A report on 50 patients
7. Secondary cytogenetic changes in acute promyelocytic leukemia: Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A Cancer and Leukemia Group B study
8. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 Trial
9. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia
10. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: Results of APL 93 trial
11. All-trans retinoic add significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
12. All-trans-retinoic acid in acute promyelocytic leukemia
13. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
14. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
15. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial
16. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML-RARα-positive acute promyelocytic leukemia
17. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
18. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the anti-PML monoclonal antibody PG-M3
19. Preliminary experience in external quality control of RT-PCR PML/RARα detection in promyelocytic leukemia
20. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
21. Nonparametric estimations from incomplete observations
22. Evaluation of survival data and two new rank order statistics arising in its consideration
23. A class of rank test procedures for censored survival data